Motixafortide+G-CSF — Competitive Intelligence Brief

Motixafortide+G-CSF (Motixafortide+G-CSF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CXCR4 antagonist. Area: Oncology.

phase 3 CXCR4 antagonist CXCR4 Oncology Small molecule

Target snapshot

Motixafortide+G-CSF (Motixafortide+G-CSF) — Guangzhou Gloria Biosciences Co., Ltd.. Motixafortide is a CXCR4 antagonist that mobilizes hematopoietic stem cells from bone marrow into peripheral blood, used in combination with G-CSF (granulocyte-colony stimulating factor) to enhance stem cell mobilization for transplantation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Motixafortide+G-CSF TARGET	Motixafortide+G-CSF	Guangzhou Gloria Biosciences Co., Ltd.	phase 3	CXCR4 antagonist	CXCR4
Fixed Dose Plerixafor	Fixed Dose Plerixafor	Genzyme, a Sanofi Company	marketed	CXCR4 antagonist	CXCR4
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
Antiretroviral medications	Antiretroviral medications	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41
Generic = Plerixafor	Generic = Plerixafor	Genzyme, a Sanofi Company	phase 3	CXCR4 antagonist	CXCR4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CXCR4 antagonist class)

1. Genzyme, a Sanofi Company · 2 drugs in this class
2. Guangzhou Gloria Biosciences Co., Ltd. · 1 drug in this class